Anko Bio: Plans to use no more than US$31 million of its own funds to participate in Weisheng Pharmaceutical's Hong Kong initial public offering

2025-02-11 21:16:19

Anko Bio announced that the company plans to use its own funds of no more than US$31 million through its wholly-owned subsidiary Anko Bio (Hong Kong) Co., Ltd. to participate as a cornerstone investor in the subscription of VISEN Pharmaceuticals' initial public offering shares issued on the Hong Kong Stock Exchange and sign a "Cornerstone Investment Agreement". Weisheng Pharmaceuticals is a late-stage biopharmaceutical company with products close to commercialization, focusing on providing treatment solutions for specific endocrine diseases in China (including Hong Kong, Macau and Taiwan).

VIS

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Singapore investigates Nvidia server export fraud
                            2025-03-03

                                    Shenzhen: By 2027, there will be more than 1,200 companies related to the embodied intelligent robot industry cluster
                            2025-03-03

                                    Hongqi Chain Store: Deputy General Managers Zhang Ying, Wan Chun, Hong Fan and Yang Yuanbin resigned
                            2025-03-03

                                    Shenzhen: Focus on supporting key core technologies such as core components of embodied intelligent robots, AI chips, and bionic dexterous hands
                            2025-03-03

                                    Intel showcases Xeon 6 processor-based network infrastructure at MWC2025
                            2025-03-03